IDStewardship

JUNE 18, 2023

In this article the story of an infectious diseases podcasts is discussed – IDpodcasts. Authored By: Richard L Oehler, MD Co-founder and Webmaster of ID Podcasts Platforms University of South Florida Morsani College of Medicine, Tampa, FL, USA Article Posted 19 June 2023 In 2007, the University of South Florida Division of Infectious Diseases (ID) was looking for a way to archive and webcast live medical presentations given by its ID faculty.

Hospitals 151

Hospitals 151

Pharmacy Times

JUNE 18, 2023

Panelists discuss the potential impact of the study data presented at the ASCO 2023 Annual Meeting, which led to significant response from the field.

114

114

pharmaphorum

JUNE 18, 2023

Rani’s ‘robotic’ pill delivers injectable osteoporosis drug Phil.

98

98

Pharmacy Times

JUNE 18, 2023

Heidi Finnes, PharmD, BCOP, FHOPA, addresses how the study data may impact the treatment of IDH1/2 mutating gliomas going forward.

122

122

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Med Ed 101

JUNE 18, 2023

NSAIDs are a commonly used class of analgesic medication. There are numerous factors that may determine which one we choose. We’ll lay out some of the most important differences between these agents and summarize this information in our NSAID comparison table at the end of this post. This information would be an excellent example of […] The post NSAID Comparison Table Including GI and CV Risks appeared first on Med Ed 101.

52

52

PharmaShots

JUNE 18, 2023

Shots: The P-III trial evaluating TransCon PTH in adults, showed sustained improvements through 52wk. as well as safety & tolerability similar to that reported for the initial 26wk. blinded portion of the trial 95% of patients in the OLE achieved independence from conventional therapy & none required active vitamin D; normal serum calcium & independence from conventional therapy (81%); mean albumin-adjusted serum calcium levels were maintained within the normal range through 52wk. of

FDA 40

FDA 40